News Releases
Jul 21, 2020
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Read more
Jul 16, 2020
ALX Oncology Announces Pricing of Initial Public Offering Read more
Jun 12, 2020
ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Read more
May 29, 2020
ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors Read more
May 18, 2020
ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25th Congress of the European Hematology Association (EHA) Read more
May 14, 2020
ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Read more
May 4, 2020
ALX Oncology Announces Appointment of Rekha Hemrajani to Board of Directors Read more
Feb 18, 2020
ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma Read more
Feb 12, 2020
ALX Oncology Announces Closing of $105 Million Series C Financing Read more
Jan 7, 2020
ALX Oncology Appoints Peter S. García as Chief Financial Officer Read more